This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

InterMune: EU to OK Esbriet Lung Drug

Stocks in this article: ITMN

Updated with new information and stock price.

BRISBANE, Calif. ( TheStreet) -- European regulators breathed new life into InterMune (ITMN) Friday, recommended the approval of the company's drug Esbriet as a treatment for the fatal lung disease idiopathic pulmonary fibrosis.

InterMune shares are surging, up $15.84, or 111%, to $30.10 in mid-morning Friday trading.

InterMune's Esbriet, also known by its scientific name pirfenidone, was rejected the U.S. Food and Drug Administration in May despite a positive recommendation from a panel of outside experts. The FDA rejection sank InterMune shares but the company moved to Europe hoping to convince regulators there to approve the drug.

And it looks as if InterMune succeeded. The positive recommendation from the Europe's Committee for Medicinal Products for Human Use (CHMP) came about a month earlier than expected.

"The benefits with Esbriet are its ability to reduce the rate of deterioration of lung function measured as reduced decline of percent predicted Forced Vital Capacity (FVC) in patients with idiopathic pulmonary fibrosis," the CHMP opinion states. "It is noted that demonstration of this effect in the clinical studies was modest but measureable. In addition, a trend in improvement of the 'six minute walk test' was observed. The most common side effects are nausea, rash, fatigue, diarrhoea, dyspepsia and photosensitivity reaction."

The CHMP recommendation still needs to be ratified by the full European Commission, which can take two or three months, InterMune said Friday.

"We are very pleased by the positive opinion adopted by the CHMP, particularly because it was achieved earlier in the regulatory process than is typical," said InterMune CEO Dan Welch, in a statement. "We are now focusing our efforts on completing our commercial launch preparations to bring Esbriet to European patients as soon as possible."

JMP Securities analyst Liisa Bayko raised her InterMune rating to market outperform from market perform and upped her price target on the stock to $35. The market opportunity for Esbriet in Europe is approximately $800 million, she said.

Esbriet would be approved as a treatment for patients with mild to moderate idiopathic pulmonary fibrosis (IPF), a disease marked by scarring of the lungs caused by the gradual buildup of fibrous tissue. As the fibrotic scar tissue accumulates, air sacs in the lungs lose their ability to transfer oxygen into the bloodstream. There are no effective treatments for IPF, and unless patients can undergo a successful lung transplant, they eventually die of the disease.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs